 | • レポートコード：MRC2Q12-16766 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、胃腸希少疾患治療の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に胃腸希少疾患治療のグローバル市場のxxx％を占める「胃腸感染症」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 胃腸希少疾患治療の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの胃腸希少疾患治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 胃腸希少疾患治療のグローバル主要プレイヤーには、Bayer Pharmaceutical、Teva pharmaceutical、Novartis AG、Sanofi、Pfizer、GlaxoSmithKline、Eli Lilly、Johnson & Johnsonなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 胃腸希少疾患治療市場は、種類と用途によって区分されます。世界の胃腸希少疾患治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 胃腸感染症、胃腸結節、その他 【用途別セグメント】 病院、診療所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 胃腸希少疾患治療製品概要 - 種類別市場（胃腸感染症、胃腸結節、その他） - 用途別市場（病院、診療所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の胃腸希少疾患治療販売量予測2017-2028 - 世界の胃腸希少疾患治療売上予測2017-2028 - 胃腸希少疾患治療の地域別販売量 - 胃腸希少疾患治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別胃腸希少疾患治療販売量 - 主要メーカー別胃腸希少疾患治療売上 - 主要メーカー別胃腸希少疾患治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（胃腸感染症、胃腸結節、その他） - 胃腸希少疾患治療の種類別販売量 - 胃腸希少疾患治療の種類別売上 - 胃腸希少疾患治療の種類別価格 ・用途別市場規模（病院、診療所、その他） - 胃腸希少疾患治療の用途別販売量 - 胃腸希少疾患治療の用途別売上 - 胃腸希少疾患治療の用途別価格 ・北米市場 - 北米の胃腸希少疾患治療市場規模（種類別、用途別） - 主要国別の胃腸希少疾患治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの胃腸希少疾患治療市場規模（種類別、用途別） - 主要国別の胃腸希少疾患治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の胃腸希少疾患治療市場規模（種類別、用途別） - 主要国別の胃腸希少疾患治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の胃腸希少疾患治療市場規模（種類別、用途別） - 主要国別の胃腸希少疾患治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの胃腸希少疾患治療市場規模（種類別、用途別） - 主要国別の胃腸希少疾患治療市場規模（トルコ、サウジアラビア） ・企業情報 Bayer Pharmaceutical、Teva pharmaceutical、Novartis AG、Sanofi、Pfizer、GlaxoSmithKline、Eli Lilly、Johnson & Johnson ・産業チェーン及び販売チャネル分析 - 胃腸希少疾患治療の産業チェーン分析 - 胃腸希少疾患治療の原材料 - 胃腸希少疾患治療の生産プロセス - 胃腸希少疾患治療の販売及びマーケティング - 胃腸希少疾患治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 胃腸希少疾患治療の産業動向 - 胃腸希少疾患治療のマーケットドライバー - 胃腸希少疾患治療の課題 - 胃腸希少疾患治療の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Gastrointestinal Rare Diseases Treatment estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Gastrointestinal Rare Diseases Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Gastrointestinal Rare Diseases Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Gastrointestinal Rare Diseases Treatment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Gastrointestinal Rare Diseases Treatment include Bayer Pharmaceutical, Teva pharmaceutical, Novartis AG, Sanofi, Pfizer, GlaxoSmithKline, Eli Lilly and Johnson & Johnson, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Gastrointestinal Rare Diseases Treatment companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Gastrointestinal Rare Diseases Treatment market. Further, it explains the major drivers and regional dynamics of the global Gastrointestinal Rare Diseases Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Bayer Pharmaceutical
Teva pharmaceutical
Novartis AG
Sanofi
Pfizer
GlaxoSmithKline
Eli Lilly
Johnson & Johnson
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Gastrointestinal Rare Diseases Treatment Segment by Type
Gastrointestinal Infection
Gastrointestinal Nodules
Other
Gastrointestinal Rare Diseases Treatment Segment by Application
Hospital
Clinic
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Gastrointestinal Rare Diseases Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Gastrointestinal Rare Diseases Treatment market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Gastrointestinal Rare Diseases Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Gastrointestinal Rare Diseases Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastrointestinal Rare Diseases Treatment revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Gastrointestinal Rare Diseases Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Gastrointestinal Rare Diseases Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer Pharmaceutical, Teva pharmaceutical, Novartis AG, Sanofi, Pfizer, GlaxoSmithKline, Eli Lilly and Johnson & Johnson, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Gastrointestinal Rare Diseases Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Rare Diseases Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastrointestinal Rare Diseases Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastrointestinal Rare Diseases Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Gastrointestinal Infection
1.2.3 Gastrointestinal Nodules
1.2.4 Other
1.3 Market by Application
1.3.1 Global Gastrointestinal Rare Diseases Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gastrointestinal Rare Diseases Treatment Market Perspective (2017-2028)
2.2 Gastrointestinal Rare Diseases Treatment Growth Trends by Region
2.2.1 Gastrointestinal Rare Diseases Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Gastrointestinal Rare Diseases Treatment Historic Market Size by Region (2017-2022)
2.2.3 Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Region (2023-2028)
2.3 Gastrointestinal Rare Diseases Treatment Market Dynamics
2.3.1 Gastrointestinal Rare Diseases Treatment Industry Trends
2.3.2 Gastrointestinal Rare Diseases Treatment Market Drivers
2.3.3 Gastrointestinal Rare Diseases Treatment Market Challenges
2.3.4 Gastrointestinal Rare Diseases Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastrointestinal Rare Diseases Treatment Players by Revenue
3.1.1 Global Top Gastrointestinal Rare Diseases Treatment Players by Revenue (2017-2022)
3.1.2 Global Gastrointestinal Rare Diseases Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Gastrointestinal Rare Diseases Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gastrointestinal Rare Diseases Treatment Revenue
3.4 Global Gastrointestinal Rare Diseases Treatment Market Concentration Ratio
3.4.1 Global Gastrointestinal Rare Diseases Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Rare Diseases Treatment Revenue in 2021
3.5 Gastrointestinal Rare Diseases Treatment Key Players Head office and Area Served
3.6 Key Players Gastrointestinal Rare Diseases Treatment Product Solution and Service
3.7 Date of Enter into Gastrointestinal Rare Diseases Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastrointestinal Rare Diseases Treatment Breakdown Data by Type
4.1 Global Gastrointestinal Rare Diseases Treatment Historic Market Size by Type (2017-2022)
4.2 Global Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Type (2023-2028)
5 Gastrointestinal Rare Diseases Treatment Breakdown Data by Application
5.1 Global Gastrointestinal Rare Diseases Treatment Historic Market Size by Application (2017-2022)
5.2 Global Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Gastrointestinal Rare Diseases Treatment Market Size (2017-2028)
6.2 North America Gastrointestinal Rare Diseases Treatment Market Size by Type
6.2.1 North America Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022)
6.2.2 North America Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028)
6.2.3 North America Gastrointestinal Rare Diseases Treatment Market Share by Type (2017-2028)
6.3 North America Gastrointestinal Rare Diseases Treatment Market Size by Application
6.3.1 North America Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022)
6.3.2 North America Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028)
6.3.3 North America Gastrointestinal Rare Diseases Treatment Market Share by Application (2017-2028)
6.4 North America Gastrointestinal Rare Diseases Treatment Market Size by Country
6.4.1 North America Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022)
6.4.2 North America Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gastrointestinal Rare Diseases Treatment Market Size (2017-2028)
7.2 Europe Gastrointestinal Rare Diseases Treatment Market Size by Type
7.2.1 Europe Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022)
7.2.2 Europe Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028)
7.2.3 Europe Gastrointestinal Rare Diseases Treatment Market Share by Type (2017-2028)
7.3 Europe Gastrointestinal Rare Diseases Treatment Market Size by Application
7.3.1 Europe Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022)
7.3.2 Europe Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028)
7.3.3 Europe Gastrointestinal Rare Diseases Treatment Market Share by Application (2017-2028)
7.4 Europe Gastrointestinal Rare Diseases Treatment Market Size by Country
7.4.1 Europe Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022)
7.4.2 Europe Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size (2017-2028)
8.2 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Type
8.2.1 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Application
8.3.1 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Region
8.4.1 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gastrointestinal Rare Diseases Treatment Market Size (2017-2028)
9.2 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Type
9.2.1 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Gastrointestinal Rare Diseases Treatment Market Share by Type (2017-2028)
9.3 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Application
9.3.1 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Gastrointestinal Rare Diseases Treatment Market Share by Application (2017-2028)
9.4 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Country
9.4.1 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size (2017-2028)
10.2 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Type
10.2.1 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Application
10.3.1 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Country
10.4.1 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bayer Pharmaceutical
11.1.1 Bayer Pharmaceutical Company Details
11.1.2 Bayer Pharmaceutical Business Overview
11.1.3 Bayer Pharmaceutical Gastrointestinal Rare Diseases Treatment Introduction
11.1.4 Bayer Pharmaceutical Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.1.5 Bayer Pharmaceutical Recent Developments
11.2 Teva pharmaceutical
11.2.1 Teva pharmaceutical Company Details
11.2.2 Teva pharmaceutical Business Overview
11.2.3 Teva pharmaceutical Gastrointestinal Rare Diseases Treatment Introduction
11.2.4 Teva pharmaceutical Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.2.5 Teva pharmaceutical Recent Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Gastrointestinal Rare Diseases Treatment Introduction
11.3.4 Novartis AG Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.3.5 Novartis AG Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Gastrointestinal Rare Diseases Treatment Introduction
11.4.4 Sanofi Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.4.5 Sanofi Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Gastrointestinal Rare Diseases Treatment Introduction
11.5.4 Pfizer Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.5.5 Pfizer Recent Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Gastrointestinal Rare Diseases Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.6.5 GlaxoSmithKline Recent Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Gastrointestinal Rare Diseases Treatment Introduction
11.7.4 Eli Lilly Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.7.5 Eli Lilly Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Gastrointestinal Rare Diseases Treatment Introduction
11.8.4 Johnson & Johnson Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
11.8.5 Johnson & Johnson Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Table 1. Global Gastrointestinal Rare Diseases Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Gastrointestinal Infection
Table 3. Key Players of Gastrointestinal Nodules
Table 4. Key Players of Other
Table 5. Global Gastrointestinal Rare Diseases Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Gastrointestinal Rare Diseases Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Gastrointestinal Rare Diseases Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Gastrointestinal Rare Diseases Treatment Market Share by Region (2017-2022)
Table 9. Global Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Gastrointestinal Rare Diseases Treatment Market Share by Region (2023-2028)
Table 11. Gastrointestinal Rare Diseases Treatment Market Trends
Table 12. Gastrointestinal Rare Diseases Treatment Market Drivers
Table 13. Gastrointestinal Rare Diseases Treatment Market Challenges
Table 14. Gastrointestinal Rare Diseases Treatment Market Restraints
Table 15. Global Gastrointestinal Rare Diseases Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Gastrointestinal Rare Diseases Treatment Revenue Share by Players (2017-2022)
Table 17. Global Top Gastrointestinal Rare Diseases Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Rare Diseases Treatment as of 2021)
Table 18. Ranking of Global Top Gastrointestinal Rare Diseases Treatment Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Gastrointestinal Rare Diseases Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Gastrointestinal Rare Diseases Treatment Product Solution and Service
Table 22. Date of Enter into Gastrointestinal Rare Diseases Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Gastrointestinal Rare Diseases Treatment Revenue Market Share by Type (2017-2022)
Table 26. Global Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Gastrointestinal Rare Diseases Treatment Revenue Market Share by Type (2023-2028)
Table 28. Global Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Gastrointestinal Rare Diseases Treatment Revenue Share by Application (2017-2022)
Table 30. Global Gastrointestinal Rare Diseases Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Gastrointestinal Rare Diseases Treatment Revenue Share by Application (2023-2028)
Table 32. North America Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 62. Bayer Pharmaceutical Company Details
Table 63. Bayer Pharmaceutical Business Overview
Table 64. Bayer Pharmaceutical Gastrointestinal Rare Diseases Treatment Product
Table 65. Bayer Pharmaceutical Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 66. Bayer Pharmaceutical Recent Developments
Table 67. Teva pharmaceutical Company Details
Table 68. Teva pharmaceutical Business Overview
Table 69. Teva pharmaceutical Gastrointestinal Rare Diseases Treatment Product
Table 70. Teva pharmaceutical Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 71. Teva pharmaceutical Recent Developments
Table 72. Novartis AG Company Details
Table 73. Novartis AG Business Overview
Table 74. Novartis AG Gastrointestinal Rare Diseases Treatment Product
Table 75. Novartis AG Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 76. Novartis AG Recent Developments
Table 77. Sanofi Company Details
Table 78. Sanofi Business Overview
Table 79. Sanofi Gastrointestinal Rare Diseases Treatment Product
Table 80. Sanofi Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 81. Sanofi Recent Developments
Table 82. Pfizer Company Details
Table 83. Pfizer Business Overview
Table 84. Pfizer Gastrointestinal Rare Diseases Treatment Product
Table 85. Pfizer Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 86. Pfizer Recent Developments
Table 87. GlaxoSmithKline Company Details
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Gastrointestinal Rare Diseases Treatment Product
Table 90. GlaxoSmithKline Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 91. GlaxoSmithKline Recent Developments
Table 92. Eli Lilly Company Details
Table 93. Eli Lilly Business Overview
Table 94. Eli Lilly Gastrointestinal Rare Diseases Treatment Product
Table 95. Eli Lilly Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 96. Eli Lilly Recent Developments
Table 97. Johnson & Johnson Company Details
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Gastrointestinal Rare Diseases Treatment Product
Table 100. Johnson & Johnson Revenue in Gastrointestinal Rare Diseases Treatment Business (2017-2022) & (US$ Million)
Table 101. Johnson & Johnson Recent Developments
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gastrointestinal Rare Diseases Treatment Market Share by Type: 2021 VS 2028
Figure 2. Gastrointestinal Infection Features
Figure 3. Gastrointestinal Nodules Features
Figure 4. Other Features
Figure 5. Global Gastrointestinal Rare Diseases Treatment Market Share by Application: 2021 VS 2028
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Other Case Studies
Figure 9. Gastrointestinal Rare Diseases Treatment Report Years Considered
Figure 10. Global Gastrointestinal Rare Diseases Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Gastrointestinal Rare Diseases Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Gastrointestinal Rare Diseases Treatment Market Share by Region: 2021 VS 2028
Figure 13. Global Gastrointestinal Rare Diseases Treatment Market Share by Players in 2021
Figure 14. Global Top Gastrointestinal Rare Diseases Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Rare Diseases Treatment as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Gastrointestinal Rare Diseases Treatment Revenue in 2021
Figure 16. North America Gastrointestinal Rare Diseases Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Gastrointestinal Rare Diseases Treatment Market Size Market Share by Type (2017-2028)
Figure 18. North America Gastrointestinal Rare Diseases Treatment Market Size Market Share by Application (2017-2028)
Figure 19. North America Gastrointestinal Rare Diseases Treatment Market Size Share by Country (2017-2028)
Figure 20. United States Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Gastrointestinal Rare Diseases Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Gastrointestinal Rare Diseases Treatment Market Size Market Share by Type (2017-2028)
Figure 24. Europe Gastrointestinal Rare Diseases Treatment Market Size Market Share by Application (2017-2028)
Figure 25. Europe Gastrointestinal Rare Diseases Treatment Market Size Share by Country (2017-2028)
Figure 26. Germany Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Gastrointestinal Rare Diseases Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Gastrointestinal Rare Diseases Treatment Market Size Share by Region (2017-2028)
Figure 36. China Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Gastrointestinal Rare Diseases Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Gastrointestinal Rare Diseases Treatment Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Gastrointestinal Rare Diseases Treatment Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Gastrointestinal Rare Diseases Treatment Market Size Share by Country (2017-2028)
Figure 46. Mexico Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Gastrointestinal Rare Diseases Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Gastrointestinal Rare Diseases Treatment Market Size Share by Country (2017-2028)
Figure 52. Turkey Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Gastrointestinal Rare Diseases Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Bayer Pharmaceutical Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 56. Teva pharmaceutical Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 57. Novartis AG Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 58. Sanofi Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 59. Pfizer Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 60. GlaxoSmithKline Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 61. Eli Lilly Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 62. Johnson & Johnson Revenue Growth Rate in Gastrointestinal Rare Diseases Treatment Business (2017-2022)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed